This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Influenza virus; cancer	CDC-like kinase 1 (CLK1); CLK4	<p>An <i>in vitro</i> study identified a dual inhibitor of CLK1 and CLK4 that could help treat diseases with aberrant mRNA splicing, such as cancer and influenza infection. A β-carboline alkaloid-based inhibitor, KH-CB19, bound to CLK1 and CLK4 and had low nanomolar IC₅₀ values. In human endothelial cell lines, KH-CB19 decreased phosphorylation of proteins that regulate splicing compared with no treatment. Next steps include investigating splicing events controlled by the CLK enzymes in influenza and cancer.</p> <p>SciBX 4(8); doi:10.1038/scibx.2011.232 Published online Feb. 24, 2011</p>	Unpatented; licensing status not applicable	<p>Fedorov, O. <i>et al. Chem. Biol.</i>; published online Jan. 28, 2011; doi:10.1016/j.chembiol.2010.11.009 Contact: Stefan Knapp, University of Oxford, Oxford, U.K. e-mail: stefan.knapp@sgc.ox.ac.uk Contact: Franz Bracher, Ludwig Maximilian University of Munich, Munich, Germany e-mail: franz.bracher@cup.uni-muenchen.de</p>